FDA Inspection 1218738 — Loxo Oncology Inc.
The FDA completed an inspection of Loxo Oncology Inc. on September 15, 2023 in Stamford, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 15, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Stamford, CT (United States)
Additional Details
Sponsor, Contract Research Organization